Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma (TA997)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 29 August 2024
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer (TA737)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 29 August 2024Published: 20 October 2021
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma (TA983)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 12 June 2024
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Oesophago-gastric cancer: assessment and management in adults (NG83)Product type:GuidanceProgramme:NICE guidelineLast updated: 4 July 2023Published: 24 January 2018
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after anti-HER2 treatment (terminated appraisal) (TA879)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 April 2023
Barrett's oesophagus and stage 1 oesophageal adenocarcinoma: monitoring and management (NG231)Product type:GuidanceProgramme:NICE guidelinePublished: 8 February 2023
Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (TA865)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 8 February 2023
Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma (TA857)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 January 2023
Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments (TA852)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 14 December 2022
Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer (TA746)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 November 2021
Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer (TA707)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 June 2021
Balloon cryoablation for squamous dysplasia of the oesophagus (IPG683)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 October 2020
Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 January 2016
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (IPG497)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 23 July 2014
Minimally invasive oesophagectomy (IPG407)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 28 September 2011
Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia (IPG355)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 22 September 2010
Palliative photodynamic therapy for advanced oesophageal cancer (IPG206)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 January 2007
Photodynamic therapy for early-stage oesophageal cancer (IPG200)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 13 December 2006
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016